Telluride Medical Partners announced today that the company has been accepted as a member of Johnson & Johnson’s JLABS program and will be a resident company at the prestigious Texas Medical Center located in Houston, TX.
“We are thrilled to be part of an elite program dedicated to innovation and providing essential resources for startup medical device companies,” says Eric Wells, Founder & CEO of Telluride Medical Partners.
Providing a capital efficient and flexible platform, the JLABS program focuses on supporting emerging medical device, pharmaceutical, consumer and digital health companies through the tenuous time between early discovery to moving a product through the path to commercialization.
“The JLABS program will provide our team access to core research facilities, capital providers, educational programs, operational capabilities and a community of like-minded entrepreneurs, all critical to advancing our early-stage med tech companies,” says Wells.
Beyond their growing network of incubation capabilities around the world, JLABS is part of the larger Johnson & Johnson Innovation family of companies including Johnson & Johnson Innovation centers, housing their deal teams and therapeutic experts for early-stage development, Johnson & Johnson Innovation – JJDC, Inc., their established venture capital arm, and Johnson & Johnson Innovation – BD, their business development group focusing on later-stage development.
In addition being a strategic partner with Johnson & Johnson through the JLABS program, Telluride Medical Partners will also be a resident company at the Texas Medical Center, the largest medical complex in the world.
“At the forefront of advancing life sciences, the Texas Medical Center is home to the world’s largest cancer center and sees over 8 million patient visits per year. Having a presence at the Texas Medical Center will provide a concentrated set of unmatched clinical use, marketing and commercialization opportunities to Telluride Medical Partners,” says Wells.